Climb Bio Inc. (CLYM)
NASDAQ: CLYMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CLYM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $539.80M
- EPS (TTM)
- -$0.81
- Dividend yield
- None
- 52-week range
- 1.64 – 18.33
- Day range
- 8.90 – 9.40
- Volume / Avg
- 770.17K / 1.38M
- Beta
- —
- Shares outstanding
- 58.74M
52-week range
CLYM stock today
On Nov 20, CLYM ended the session at $9.19, shedding $0.09 (0.97%), versus the S&P 500's 3.70% decline. Shares are 49.9% below their 52-week high of $18.33, set on Aug 25, 2026 and 462.1% above the 52-week low of $1.64, in the middle of the past year's range. CLYM is up 129.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 440.6%.
Climb Bio has posted a net loss over the last twelve months (EPS of -$0.81), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Climb Bio
Company profileClimb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
- Headquarters
- Wellesley Hills, MA
- Employees
- 28
- IPO year
- 2021
- Website
- climbbio.com
Financial highlights
Full financialsClimb Bio reported a net loss of $59.9 million, compared with a loss of $73.9 million a year earlier. Diluted earnings per share came in at -$0.88.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-59.85M | $-73.90M | $-35.12M | $-45.24M | $-47.48M |
| EPS (diluted) | $-0.88 | $-1.53 | $-1.30 | $-1.72 | $-4.24 |
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$28.40+209.03%
- Strong buy 2
- Buy 14
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.18 vs $-0.20
- Surprise
- +10.00%
CLYM news
All CLYM news- Wedbush keeps Climb Bio on Best Ideas List, raises price targetInvesting.com
- Climb Bio Non-GAAP EPS of -$0.18 beats by $0.02Seeking Alpha
- Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and ExpositionGlobeNewswire
- Climb Bio, Inc. Announces Initial PrisMN Phase 2 Data for Budoprutug in Primary Membranous NephropathyNasdaq
- Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026GlobeNewswire
- Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026GlobeNewswire
- Why is Climb Bio stock surging today?Investing.com
Climb Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ACRSAclaris Therapeutics Inc. | 3.44 | -1.71% | $545.63M | vs CLYM |
| AVBPArriVent BioPharma Inc. | 10.52 | -6.57% | $544.13M | vs CLYM |
| CBIOCrescent Biopharma Inc. | 13.00 | +0.70% | $543.21M | vs CLYM |
| ANLAdlai Nortye Group Ltd. ADR | 8.55 | -5.63% | $550.60M | vs CLYM |
| BCAXBicara Therapeutics Inc. | 8.44 | -7.46% | $560.31M | vs CLYM |
| GERNGeron Corporation | 0.8707 | -4.63% | $560.94M | vs CLYM |
| ZVRAZevra Therapeutics Inc. | 8.76 | -3.42% | $521.26M | vs CLYM |
| ALMSAlumis Inc. | 3.96 | -8.54% | $514.09M | vs CLYM |
Indexes, lists and sector
Climb Bio stock FAQ
What is Climb Bio's stock price today?
CLYM last traded at $9.19 as of Nov 20, 4:00 PM EST, down 0.97% on the day. Prices are delayed at least 15 minutes.
Who is Climb Bio's CEO?
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc is the chief executive officer of Climb Bio Inc., which has about 28 employees.
What is the CLYM 52-week high?
The 52-week high for CLYM is $18.33 and the 52-week low is $1.64. The stock is currently 49.9% below its high.